RedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced agreements with Cosmo Pharmaceuticals NV to manufacture RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Movantik is a prescribed oral peripherally acting mu-opioid receptor antagonist in the U.S. specifically to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
RHB-204 is an investigational proprietary, a fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine.
Last month, RedHill entered into a manufacturing agreement with Cosmo Pharmaceuticals to expand its manufacturing capacity for opaganib (Yeliva, ABC294640), currently in a Phase 2a study in advanced cholangiocarcinoma and a Phase 2 study in prostate cancer. Opaganib is also being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study and has demonstrated positive safety and efficacy signals.
Price Action: RDHL stock dropped 4.2% at $10.38 in market trading hours on last check Thursday.

Momentum2.63

Growth14.64

Quality-

Value43.90

Short

Medium

Long